A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of LNS8801 in Patients With Advanced Cancer
What is the purpose of this trial?
LNS-101 is a multi-center study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of LNS8801 in patients with advanced cancer. This Phase 1, first-in-human, open-label, multi-center study is designed to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D). LNS8801 will be administered until disease progression or unacceptable toxicity.
- Trial withLinnaeus Therapeutics, Inc.
- Start Date07/25/2022
- End Date10/30/2023
- Last Updated07/26/2022
- Study HIC#2000026326